Nivalis Therapeutics Names David Rodman As Chief Medical Officer

Nivalis Therapeutics Inc

disclosed that it hired David Rodman as its chief medical officer and executive vice president of discovery. Until recently, he was the CMO and EVP of R&D at miRagen Therapeutics. Nivalis Therapeutics indicated that Rodman would lead the discovery and clinical development strategy and operations. That included advancement of N91115, its lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The company's President and CEO, Jon Congleton, said that "We are thrilled to welcome David to the Nivalis team. He brings extensive expertise in clinical research and development along with a deep understanding of the unique needs of the CF community." He continued to say that "His leadership experience in both industry and clinical settings, coupled with his talent in bringing innovative respiratory products to market, will be invaluable as we continue to develop and expand our product pipeline." For his part, Rodman said that "I am excited to be joining the Nivalis team at this pivotal time in the Company's evolution. I see significant opportunity in the Company's S-nitrosoglutathione reductase (GSNOR) inhibition technology and look forward to helping Nivalis deliver on its mission to bring innovative solutions that improve the lives of people with CF." Shares of the company shed 1.07% on Friday.